Blocking IL-1 in systemic inflammation

Journal of Experimental Medicine

Volumn 201, Issue 9, 2005, Pages 1355-1359

  Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA;

ANEMIA; CYTOKINE RELEASE; FEVER; HUMAN; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOSIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

ARTHRITIS, JUVENILE RHEUMATOID; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18644374105     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20050640     Document Type: Review

References (27)

1. Andrei, C., C. Dazzi, L. Lotti, M.R. Torrisi, G. Chimini, and A. Rubartelli. 1999. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell. 10:1463-1475.
2. Tschopp, J., F. Martinon, and K. Burns. 2003. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4:95-104.
3. Gudipaty, L., J. Munetz, P.A. Verhoef, and G.R. Dubyak. 2003. Essential role for Ca2+ in the regulation of IL-1β secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells. Am. J. Physiol. Cell Physiol. 285:C286-C299.
4. Solle, M., J. Labasi, D.G. Perregaux, E. Stam, N. Petrushova, B.H. Koller, R.J. Griffiths, and C.A. Gabel. 2001. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. 276:125-132.
5. Elssner, A., M. Duncan, M. Gavrilin, and M.D. Wewers. 2004. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 172:4987-4994.
6. Andrei, C., P. Margiocco, A. Poggi, L.V. Lotti, M.R. Torrisi, and A. Rubartelli. 2004. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc. Natl. Acad. Sci. USA. 101:9745-9750.
7. Pascual, V., F. Allantaz, E. Arce, M. Punaro, and J. Banchereau. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1477-1484.
8. Verbsky, J.W., and A.J. White. 2004. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 31:2071-2075.
9. Economides, A.N., L.R. Carpenter, J.S. Rudge, V. Wong, E.M. Kochler-Stec, C. Hartnett, E.A. Pyles, X. Xu, T.J. Daly, M.R. Young, et al. 2003. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9:47-52.
10. Fitzgerald, A.A., S.A. LeClercq, A. Yan, J.E. Homik, and C.A. Dinarello. 2005. Rapid response to anakinra in patients with refractory adult onset Still's disease. Arthritis Rheum. In press.
11. Mantovani, A., M. Muzio, P. Ghezzi, C. Colotta, and M. Introna. 1998. Regulation of inhibitory pathways of the interleukin-1 system. Ann. N. Y. Acad. Sci. 840:338-351.
12. Dinarello, C.A. 1996. Biological basis for interleukin-1 in disease. Blood. 87:2095-2147.
13. Hoffman, H.M., S. Rosengren, D.L. Boyle, J.Y. Cho, J. Nayar, J.L. Mueller, J.P. Anderson, A.A. Wanderer, and G.S. Firestein. 2004. Prevention of cold-associated acute inflammation in familail cold autoinflammatory syndrome by interleukin-1 receptor antagonist prevents. Lancet. 364:1779-1785.
14. Dailey, N.J., I. Aksentijevich, J.J. Chae, R. Wesley, C. Snyder, M. Magalnick, W.T. Watford, A. Gelabert, J. Jones, T.-H. Pham, et al. 2004. Interleukin-1 receptor antagonist anakinra in the treatment of neonatal onset multisystem inflammatory disease. Arthritis Rheum. 50:S440.
15. Hawkins, P.N., H.J. Lachmann, E. Aganna, and M.F. McDermott. 2004. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50:607-612.
16. Lovell, D.J., and S.L. Bowyer. 2003. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum. 52:1283-1286.
17. Agostini, L., F. Martinon, K. Burns, M.F. McDermott, P.N. Hawkins, and J. Tschopp. 2004. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity. 20:319-325.
18. Frenkel, J., N.M. Wulffrant, and W. Kuis. 2004. Anakinra in mutation-negative NO-MID-CINCA syndrome: comment on articles by Hawkins et al and Hoffman and Patel. Arthr Rheumat 50:3738-3739.
19. Dierselhuis, M.P., J. Frenkel, N.M. Wulffraat, and J.J. Boelens. 2005. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology. 44:406-408.
20. Shoham, N.G., M. Centola, E. Mansfield, K.M. Hull, G. Wood, C.A. Wise, and D.L. Kastner. 2003. Pyrin binds the PSTP1P1/ CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA. 100:13501-13506.
21. Chae, J.J., H.D. Komarow, J. Cheng, G. Wood, N. Raben, P.P. Liu, and D.L. Kastner. 2003. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell. 11:591-604.
22. Randle, J.C., M.W. Harding, G. Ku, M. Schonharting, and R. Kurrle. 2001. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig. Drugs. 10:1207-1209.
23. Kahlenberg, J.M., and G.R. Dubyak. 2004. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am. J. Physiol. Cell Physiol. 286:C1100-C1108.
24. Colotta, F., S.K. Dower, J.E. Sims, and A. Mantovani. 1994. The type II "decoy" receptor: a novel regulatory pathway for interleukin-1. Immunol. Today. 15:562-566.
25. Jensen, L.E., M. Muzio, A. Mantovani, and A.S. Whitehead. 2000. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J. Immunol. 164:5277-5286.
26. Smith, D.E., R. Hanna, F. Della, H. Moore, H. Chen, A.M. Farese, T.J. MacVittie, G.D. Virca, and J.E. Sims. 2003. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 18:87-96.
27. Dinarello, C.A. 2004. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J. Endotoxin Res. 10:201-222.